The Optimal Anti-Coagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation (OCEAN) trial

• Published in: The American heart journal Vol. 197; pp. 124 - 132
• Main Authors: Verma, Atul, Ha, Andrew C.T., Kirchhof, Paulus, Hindricks, Gerhard, Healey, Jeff S., Hill, Michael D., Sharma, Mukul, Wyse, D. George, Champagne, Jean, Essebag, Vidal, Wells, George, Gupta, Dhiraj, Heidbuchel, Hein, Sanders, Prashanthan, Birnie, David H.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2018; Elsevier Limited
• Subjects: Ablation; Acetylsalicylic acid; Anticoagulants; Antiplatelet therapy; Arrhythmia; Bleeding; Brain; Cardiac arrhythmia; Catheters; Clinical trials; Economic analysis; Embolism; Fibrillation; Health risks; Hemorrhage; Ischemia; Magnetic resonance imaging; Measuring techniques; Medical instruments; Neuroimaging; NMR; Nuclear magnetic resonance; Patients; Psychology; Quality of life; Radiofrequency ablation; Risk analysis; Risk assessment; Risk factors; Stroke; Transient ischemic attack; Asia

The optimal long-term antithrombotic regimen for patients after successful catheter-based atrial fibrillation (AF) ablation is not well defined. Presently, practice variation exists, and the benefits of oral anticoagulation over antiplatelet therapy across the entire spectrum of stroke risk profile...